Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene–drug pairs
- 1 August 2014
- journal article
- Published by Future Medicine Ltd in Pharmacogenomics
- Vol. 15 (11), 1405-1416
- https://doi.org/10.2217/pgs.14.103
Abstract
The use of proton pump inhibitors (PPIs) in the treatment of gastroesophageal reflux and related diseases is increasing, especially in the pediatric population. Prolonged use of PPIs has been associated with several adverse effects, including potentially life-threatening gastric and respiratory infections, which are related to dose or to the degree of gastric acid suppression. Genetic variation in the CYP2C19 gene gives rise to poor and extensive metabolizer phenotypes, which influence PPI clearance, efficacy and exposure. A recent paper linked lansoprazole-associated respiratory infections in children with the poor metabolizer phenotype. The case is made for implementing pharmacogenomic testing for the CYP2C19–PPI gene–drug pair and to dose accordingly in order to minimize PPI-associated infections.Keywords
This publication has 100 references indexed in Scilit:
- Proton Pump Inhibitors in PediatricsPediatric Drugs, 2013
- CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteersEuropean Journal of Clinical Pharmacology, 2012
- Personalizing medicine with clinical pharmacogeneticsGenetics in Medicine, 2011
- Risk of Community-Acquired Pneumonia in Veteran Patients to Whom Proton Pump Inhibitors Were DispensedClinical Infectious Diseases, 2011
- Higher Rate of Bronchoalveolar Lavage Culture Positivity in Children with Nonacid Reflux and Respiratory DisordersThe Journal of Pediatrics, 2011
- CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research NetworkClinical Pharmacology & Therapeutics, 2011
- Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control studyPharmacoepidemiology and Drug Safety, 2010
- Use of Proton Pump Inhibitors and the Risk of Community-Acquired PneumoniaArchives of Internal Medicine, 2007
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive DrugsJAMA, 2004